Transcripta Bio Announces $24 Million Funding
2026-07-22
Tweet
PALO ALTO, CA, Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, announced it has raised $24 million since its Series A.
Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, announced it has raised $24 million since its Series A to advance IND-enabling studies across its portfolio and support clinical preparation in its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs.
Mayo Clinic and Omnimed join existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices as the company advances its pipeline toward human clinical trials.
The company's pipeline spans four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease (HD).
Mayo Clinic and Omnimed join existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices as the company advances its pipeline toward human clinical trials.
The company's pipeline spans four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease (HD).
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
